Veracyte Inc. (VCYT) — closed signal from July 27, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on October 25, 2025.
Predicted vs. what happened
What happened
Reached its target in 39 days.
The thesis — published July 27, 2025
When Veracyte is added to the S&P SmallCap 600 on 7/29, funds that track that list must buy about two weeks of normal trading volume. Plus, ARK recently bought 262,000 shares and sales have been growing about 20% each year. The price is still near its recent average of $25 and more buyers are coming in, so the share price could climb to about $32 within three months.
Primary drivers
- Joining the S&P SmallCap 600 on 7/29 makes many index funds buy shares.
- ARK fund bought 262,000 shares, showing big investors believe in the company.
- Sales have risen about 20% a year and high 60% margins support steady growth.
- Price holding near recent average with more buyers hints at a rise after 7/29.
How it played out
VCYT: target reached in 39 days
Lyra published VCYT at $25.25 on 2025-07-27, with a short-term window through 2025-10-25. The thesis expected 25% growth and a move to $31.56. It pointed to Veracyte joining the S&P SmallCap 600 on 7/29, forced index buying, ARK buying 262,000 shares, sales rising about 20% a year, high 60% margins, and the price holding near $25.
Inside the window, VCYT reached the target in 39 days. The peak was $37.07 on 2025-10-20, with a 46.8% gain. It ended at $36.73 on 2025-10-25. The published thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.